Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cost of Revenue: 2013-2025

Historic Cost of Revenue for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to $93.2 million.

  • Amphastar Pharmaceuticals' Cost of Revenue rose 4.39% to $93.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $366.3 million, marking a year-over-year increase of 7.66%. This contributed to the annual value of $358.1 million for FY2024, which is 22.11% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Cost of Revenue of $93.2 million as of Q3 2025, which was up 5.99% from $87.9 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Cost of Revenue's 5-year high stood at $99.9 million during Q4 2024, with a 5-year trough of $54.3 million in Q2 2021.
  • Its 3-year average for Cost of Revenue is $83.4 million, with a median of $85.3 million in 2025.
  • Its Cost of Revenue has fluctuated over the past 5 years, first surged by 30.03% in 2021, then fell by 1.23% in 2022.
  • Over the past 5 years, Amphastar Pharmaceuticals' Cost of Revenue (Quarterly) stood at $64.7 million in 2021, then dropped by 1.23% to $63.9 million in 2022, then grew by 28.36% to $82.0 million in 2023, then increased by 21.85% to $99.9 million in 2024, then increased by 4.39% to $93.2 million in 2025.
  • Its Cost of Revenue stands at $93.2 million for Q3 2025, versus $87.9 million for Q2 2025 and $85.3 million for Q1 2025.